SARS-CoV-2 Infects Human Engineered Heart Tissues and Models COVID-19 Myocarditis
Adam L. Bailey, Oleksandr Dmytrenko, Lina Greenberg, Andrea L. Bredemeyer, Pan Ma, Jing Liu, Vinay Penna, Lulu Lai, Emma S. Winkler, Sanja Sviben, Erin Brooks, Ajith P. Nair, Kent A. Heck, Aniket S. Rali, Leo Simpson, Mehrdad Saririan, Dan Hobohm, W. Tom Stump, James A. Fitzpatrick, Xuping Xie, Pei-Yong Shi, J. Travis Hinson, Weng-Tein Gi, Constanze Schmidt, Florian Leuschner, Chieh-Yu Lin, Michael S. Diamond, Michael J. Greenberg, & Kory J. Lavine (2021). “SARS-CoV-2 Infects Human Engineered Heart Tissues and Models COVID-19 Myocarditis” JACC Basic Transl Sci. 2021 Feb 26. doi: 10.1016/j.jacbts.2021.01.002. Online ahead of print. (Abstract)

For over 70 years, the anticoagulant Warfarin has been a first line defense used to treat and prevent heart attacks, strokes, and other cardiovascular diseases. Warfarin inhibits the Human Vitamin K Epoxide Reductase (VKOR) to hinder coagulation. However, despite being the most popular prescribed anticoagulant, Warfarin has a very narrow range of efficacy and overdose often induces severe, sometimes fatal bleeding. In older adults, one-third of hospitalization for adverse drug reaction are due to warfarin use.